Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma

Changhoon Yoo; Dok Hyun Yoon; Shinkyo Yoon; Shin Kim; Jooryung Huh; Chan Jeong Park; Sang Wook Lee; Cheolwon Suh

doi:10.3109/10428194.2014.917640

Prognostic impact of β₂-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma

Changhoon Yoo, Dok Hyun Yoon, Shinkyo Yoon, Shin Kim, Jooryung Huh, Chan Jeong Park, Sang Wook Lee, Cheolwon Suh

Pediatrics - Blood/Marrow Transplant

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Although serum β₂-microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, it has not been comprehensively investigated in non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Between January 2000 and May 2013, a total of 174 patients with non-gastric MALT lymphoma were identified from a prospectively developed database. Baseline serum B2M was elevated in 17 (10%) patients. In univariate analysis, serum B2M ≥ 2.5 mg/L was significantly associated with progression-free survival (PFS, p < 0.001) and overall survival (OS, p < 0.001). Multivariate analysis identified serum B2M as an independent prognostic factor in PFS (hazard ratio [HR] = 3.5, 95% confidence interval [CI]: 1.2-10.0; p = 0.02) and OS (HR = 26.9, 95% CI: 2.7-269.7; p = 0.005), after adjustment for IPI and treatment modalities. Baseline serum B2M is an independent prognostic factor in patients with non-gastric MALT lymphoma.

Original language	English (US)
Pages (from-to)	688-693
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	56
Issue number	3
DOIs	https://doi.org/10.3109/10428194.2014.917640
State	Published - Mar 1 2015

Bibliographical note

Publisher Copyright:
© 2014 Informa UK, Ltd.

Keywords

marginal zone lymphoma
prognostic factor
β-Microglobulin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3109/10428194.2014.917640

OpenUrl availability

Full text

Cite this

@article{3921deedb9a84121bd991f1148eb591c,

title = "Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma",

abstract = "Although serum β2-microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, it has not been comprehensively investigated in non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Between January 2000 and May 2013, a total of 174 patients with non-gastric MALT lymphoma were identified from a prospectively developed database. Baseline serum B2M was elevated in 17 (10%) patients. In univariate analysis, serum B2M ≥ 2.5 mg/L was significantly associated with progression-free survival (PFS, p < 0.001) and overall survival (OS, p < 0.001). Multivariate analysis identified serum B2M as an independent prognostic factor in PFS (hazard ratio [HR] = 3.5, 95% confidence interval [CI]: 1.2-10.0; p = 0.02) and OS (HR = 26.9, 95% CI: 2.7-269.7; p = 0.005), after adjustment for IPI and treatment modalities. Baseline serum B2M is an independent prognostic factor in patients with non-gastric MALT lymphoma.",

keywords = "marginal zone lymphoma, prognostic factor, β-Microglobulin",

author = "Changhoon Yoo and Yoon, {Dok Hyun} and Shinkyo Yoon and Shin Kim and Jooryung Huh and Park, {Chan Jeong} and Lee, {Sang Wook} and Cheolwon Suh",

note = "Publisher Copyright: {\textcopyright} 2014 Informa UK, Ltd.",

year = "2015",

month = mar,

day = "1",

doi = "10.3109/10428194.2014.917640",

language = "English (US)",

volume = "56",

pages = "688--693",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma

AU - Yoo, Changhoon

AU - Yoon, Dok Hyun

AU - Yoon, Shinkyo

AU - Kim, Shin

AU - Huh, Jooryung

AU - Park, Chan Jeong

AU - Lee, Sang Wook

AU - Suh, Cheolwon

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Although serum β2-microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, it has not been comprehensively investigated in non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Between January 2000 and May 2013, a total of 174 patients with non-gastric MALT lymphoma were identified from a prospectively developed database. Baseline serum B2M was elevated in 17 (10%) patients. In univariate analysis, serum B2M ≥ 2.5 mg/L was significantly associated with progression-free survival (PFS, p < 0.001) and overall survival (OS, p < 0.001). Multivariate analysis identified serum B2M as an independent prognostic factor in PFS (hazard ratio [HR] = 3.5, 95% confidence interval [CI]: 1.2-10.0; p = 0.02) and OS (HR = 26.9, 95% CI: 2.7-269.7; p = 0.005), after adjustment for IPI and treatment modalities. Baseline serum B2M is an independent prognostic factor in patients with non-gastric MALT lymphoma.

AB - Although serum β2-microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, it has not been comprehensively investigated in non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Between January 2000 and May 2013, a total of 174 patients with non-gastric MALT lymphoma were identified from a prospectively developed database. Baseline serum B2M was elevated in 17 (10%) patients. In univariate analysis, serum B2M ≥ 2.5 mg/L was significantly associated with progression-free survival (PFS, p < 0.001) and overall survival (OS, p < 0.001). Multivariate analysis identified serum B2M as an independent prognostic factor in PFS (hazard ratio [HR] = 3.5, 95% confidence interval [CI]: 1.2-10.0; p = 0.02) and OS (HR = 26.9, 95% CI: 2.7-269.7; p = 0.005), after adjustment for IPI and treatment modalities. Baseline serum B2M is an independent prognostic factor in patients with non-gastric MALT lymphoma.

KW - marginal zone lymphoma

KW - prognostic factor

KW - β-Microglobulin

UR - http://www.scopus.com/inward/record.url?scp=84924706263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924706263&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.917640

DO - 10.3109/10428194.2014.917640

M3 - Article

C2 - 24913511

AN - SCOPUS:84924706263

SN - 1042-8194

VL - 56

SP - 688

EP - 693

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -